# Seven Fleet Capital Management LP

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/seven-fleet-capital-management-lp
Canonical HTML page: https://getbiobrief.com/entity/seven-fleet-capital-management-lp

## Timeline

- **2026-06-30**: Schikan sells 30,712 shares — Schikan sold an additional 30,712 shares at $35.49, totaling $1,089,969.
- **2026-06-29**: Schikan sells 6,888 shares — Director Johannes Gerardus Chri Schikan sold 6,888 shares at $35.05, totaling $241,424.
- **2026-06-16**: HC Wainwright reiterates buy rating — HC Wainwright reaffirmed its buy rating on Pharvaris shares.
- **2026-05-13**: UBS sets $74 price target — UBS Group issued a research note with a $74 price objective on Pharvaris.
- **2026-05-12**: Q1 earnings beat — Pharvaris reported Q1 EPS of -$0.70, beating the consensus estimate of -$0.82.
- **2026-04-21**: Weiss Ratings issues sell (d-) rating — Weiss Ratings reaffirmed a sell rating on Pharvaris shares, citing financial risks.
- **2026-04-07**: Wedbush raises price target to $42 — Wedbush lifted its price target on Pharvaris from $41 to $42 with an outperform rating.

## Recent coverage (1 stories)

### $1.33M Insider Sale at Pharvaris: What It Means for HAE Drug Catalysts
2026-07-11 21:42:38 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Director Johannes Schikan sold $1.33 million in Pharvaris stock just as the company approaches critical Phase 3 readouts for its oral HAE therapy. With analysts split and institutions buying, the insider move adds a wrinkle to the risk-reward calculus ahead of binary clinical data.
Full story: https://getbiobrief.com/story/pharvaris-insider-sale-1.33m-hae-catalysts

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.